Does pharmacist-supervised intervention through pharmaceutical care program influence direct healthcare cost burden of newly diagnosed diabetics in a tertiary care teaching hospital in Nepal: a non-clinical randomised controlled trial approach

Upadhyay, Dinesh K.; Ibrahim, Mohamed Izham Mohamed; Mishra, Pranaya; Alurkar, Vijay Madhav; Ansari, Mukhtar

doi:10.1186/s40199-016-0145-x

Cited by 13 publications

(26 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EU MS will be able to use common HTA tools, methodologies and procedures across the EU, working together in four sections: 1) on joint clinical assessments focusing on the most innovative health technologies with the most potential impact for patients; 2) on joint scientific consultations whereby developers can seek advice from HTA authorities; 3) on identification of emerging health technologies to identify promising technologies early; and 4) on continuing voluntary cooperation in other areas. Finally, with real-world evidence (RWE) Pharmaceutical Sciences deals with accelerated drug research, and pharmacoeconomic studies are providing a strategic framework for pharmacy practice and pharmaceutical policy [23][24][25][26][27][28][29][30][31][32][33][34][35][36].…”

Section: Discussionmentioning

confidence: 99%

The use of medicines in exceptional circumstances in Spain: adding perspective to early access

Pérez-Surio

Ortíz

2018

Drugs Ther Perspect

View full text Add to dashboard Cite

The use of medicines in exceptional circumstances refers to the use of non authorized medicines, or which are used outside the authorized conditions, and includes three different situations: (a) The use of medication in research or compassionate use; (b) The use of foreign medicines (medicines unauthorized in one country but authorized in others), and; (c) Off-label use (medicines outside the authorized conditions of use, or use out of indication). In Spain we intend to govern the period between authorization and price, with standard criteria, through Therapeutic Positioning Reports. The keys to manage this situation, in our opinion, could be: (1) A restrictive interpretation of access that can be made through the Therapeutic Positioning Reports, (2) with an agreement so that the medication is paid at the price at which finally it is financed, and (3) restricting this period of time to only a few months or less (e.g. orphan medicines). Introduction Access to medicines in exceptional circumstances (compassionate use, off-label use, and foreign drugs) is a health need. Many of these non-covered pharmacological needs are given in committed clinical situations, understanding such as chronic or severely debilitating diseases or those that they place patient's life in danger, and cannot be satisfactorily addressed with one authorized and commercialized medication. The use of medicines in exceptional circumstances refers to the use of non authorized medicines, or which are used outside the authorized conditions, and includes three situations different well delimited in the Spanish Royal Decree (RD) 1015/2009 regulating the availability of medicinal products in special situations: (a) The use of medication in research or compassionate use; (b) The use of foreign medicines (medicines unauthorized in Spain but authorized in other countries, and; (c) Off-label use (medicines outside the authorized conditions of use or use out of indication). The legislation limits the use of each one of them for those exceptional circumstances in which there is no other commercial therapeutic alternative and describe two different situations for each one, the individual use or those situations in which there may be a collective use (which the legislation states, respectively, temporary use authorization, use protocol or recommendations of use). The Spanish procedure is absolutely guarantor [1], requiring for its authorization: 1) the informed consent of the patient; 2) the request of a specialist physician; 3) the conformity of the Medical Chief Director of the healthcare center; 4) the conformity of the promoter or pharmaceutical company, and, finally; 5) the authorization by the Spanish Agency of Medicines and Medical Devices.

show abstract

Section: Discussionmentioning

confidence: 99%

The use of medicines in exceptional circumstances in Spain: adding perspective to early access

Pérez-Surio

Ortíz

2018

Drugs Ther Perspect

View full text Add to dashboard Cite

show abstract

“…[ 22 ] Ten patients were excluded from the study because they did not complete their follow-ups and hence further study was carried out with 152 patients (CG [ n = 50], T1G [ n = 51], and T2G [ n = 51]). [ 15 23 ]…”

Section: Aterials and M Ethodsmentioning

confidence: 99%

“…The aim to use the diabetic kit only in T2G patients was to identify any significant change in patients’ weighted impact scores (WISs) and average weighted impact scores (AWISs) (indicating HRQoL) between T1G and T2G due to this extra demonstration of diabetic kit. [ 15 23 ]…”

Section: Aterials and M Ethodsmentioning

confidence: 99%

See 1 more Smart Citation

Impact assessment of pharmacist-supervised intervention on health-related quality of life of newly diagnosed diabetics: A pre-post design

et al. 2020

Self Cite

View full text Add to dashboard Cite

“…88 The pharmacist contribution in minimizing direct healthcare cost burden in patients with diabetes was described. 89 An average costs for inpatient hospitalization and ED admissions were significantly higher in the preintervention period than in the post-intervention period for patients with DM as the primary or secondary diagnosis ($2434 versus $636) respectively, which indicates, pharmacist interventions under a collaborative drug therapy agreement provided a great reduction in costs for inpatient hospitalization and ED services. 90 Pharmacists had served as a resource to other health care providers and payers to assure safe, appropriate, cost-effective diabetes medication use.…”

mentioning

confidence: 94%

The Current Scenario of Clinical Pharmacy Service in the Management of Patients with Diabetes Mellitus and Related Complications: Review Article

Demoz¹,

Gebremariam²,

Legesse³

2018

IJOPP

View full text Add to dashboard Cite

Diabetes Mellitus (DM) is a group of metabolic disorder characterized by defect in insulin secretion, insulin action or both. The prevalence of diabetes continues to rise worldwide, placed in an increasing burden on healthcare systems and for the individual payers. This review is aimed to organize and examines the contribution of pharmacist in people living with diabetes mellitus and reviewed to whether the extent of diabetes management interventions delivered by pharmacist is successful in achieving the goal of therapy in DM patients. Many studies revealed and confirmed that the positive impacts of pharmacists intervention on monitoring of blood glucose level, blood pressure, lipid profiles, body mass indexes, diabetes related complications, economic benefits, improving health related quality of life, drug-related problems, adherence to medication, provision of patient education and counseling services, medication therapy management services and other pharmaceutical care services that enhance the clinical outcomes in diabetes patients were better than the usual care services. In all cases, it was proven that the intervention was successful in achieving the goals of therapy in diabetes patients and reducing other complications associated with the disease. Therefore, pharmacist integration into a health care team had shown to be effective in improving a number of clinical health outcomes in diabetic patients. This may be helpful to realize the current progress of pharmacist'srole in people living with diabetes and associated complications.

show abstract

Does pharmacist-supervised intervention through pharmaceutical care program influence direct healthcare cost burden of newly diagnosed diabetics in a tertiary care teaching hospital in Nepal: a non-clinical randomised controlled trial approach

Cited by 13 publications

References 21 publications

The use of medicines in exceptional circumstances in Spain: adding perspective to early access

The use of medicines in exceptional circumstances in Spain: adding perspective to early access

Impact assessment of pharmacist-supervised intervention on health-related quality of life of newly diagnosed diabetics: A pre-post design

The Current Scenario of Clinical Pharmacy Service in the Management of Patients with Diabetes Mellitus and Related Complications: Review Article

Contact Info

Product

Resources

About